Navigating Therapeutic Challenges in BRAF-Mutated NSCLC: Non-V600 Mutations, Immunotherapy, and Overcoming Resistance

Area of Science:

• Oncology
• Genomics
• Pharmacology

Background:

• BRAF mutations are rare but therapeutically challenging in non-small cell lung cancer (NSCLC).
• Targeted therapies exist for BRAF V600E mutations, but not for class II and III mutations, creating treatment uncertainty.
• Immunotherapy shows potential efficacy in BRAF-mutated NSCLC, especially in smokers, despite limited benefit in other genomic alterations.

Purpose of the Study:

• To explore critical management challenges in BRAF-mutated NSCLC.
• To provide a comprehensive summary of current evidence on BRAF-mutated NSCLC treatments.
• To highlight ongoing clinical trials addressing treatment gaps and resistance mechanisms.

Main Methods:

• Literature review of current evidence on BRAF-mutated NSCLC.
• Analysis of therapeutic strategies, including targeted inhibitors and immunotherapy.
• Examination of resistance mechanisms to BRAF pathway inhibitors.

Main Results:

• BRAF/MEK inhibitor combinations improve survival for V600E mutations.
• No targeted therapies are available for class II/III BRAF mutations.
• Immunotherapy demonstrates comparable efficacy in BRAF-mutated NSCLC, particularly in smokers.

Conclusions:

• BRAF-mutated NSCLC requires novel therapeutic strategies beyond current inhibitors.
• Resistance to BRAF inhibitors is inevitable, necessitating research into overcoming these mechanisms.
• Further clinical trials are crucial to address unmet needs and improve outcomes for BRAF-mutated NSCLC patients.